Study ID: COG AAML08B1
Biology Study of Transient Myeloproliferative Disorder (TMD) in Children With Down Syndrome (DS)
This study will provide pre-clinical data (i.e., cytarabine drug sensitivity testing; functional polymorphisms in drug detoxification genes; biologic targets for drug therapy) to support the development of future therapeutic trials for TMD patients. Participants in this study have been diagnosed with a condition called Transient Myeloproliferative Disorder (TMD). TMD is found in young babies (less than 3 months old) with Down syndrome and is caused by abnormal blood cells that travel throughout the body. This study will utilize a mortality risk-based classification system to characterize the distinctive biological features of each TMD risk group and correlate these findings to outcome. Evidence based treatment recommendations have been included in Appendix V of this protocol to assist physicians with clinical management decisions and to encourage uniform treatment pathways for infants with TMD.
Fargo Region, Sioux Falls Region
Kayelyn Wagner, MD,Samuel Anim, MD
AML (Acute Myelogenic Leukemia)
Active - Open to Accrual
For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.